Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles

Publisher Website
Google Scholar
Abstract
We examined the effects of several E‐ring and F‐ring isoprostanes on mechanical activity in pulmonary artery and vein. 8‐iso PGE2 and 8‐iso PGF2α were powerful spasmogens in human vasculature and in canine pulmonary vein. 8‐iso PGE1 and 8‐iso PGF2β also exhibited moderate spasmogenic activity in canine pulmonary vein; 8‐iso PGF1α, 8‐iso PGF1β, and 8‐iso PGF3α were generally ineffective. Canine pulmonary arteries did not exhibit excitatory responses to any of the isoprostanes. The spasmogenic effects of 8‐iso PGE2 were markedly attenuated by the TP‐receptor blocker ICI 192605 and by the EP‐receptor blocker AH 6809 (−log KB=8.4 and 5.7, respectively). PGE2 was a very weak agonist (∼100 fold less so than 8‐iso PGE2). In the presence of ICI 192605 (10−6 M), 8‐iso PGE1 evoked modest dose‐dependent relaxations in human and canine pulmonary vein, and in canine pulmonary artery, but not in the human pulmonary artery. The other isoprostanes were generally ineffective as vasodilators in the pulmonary vasculature of both species. The spasmogenic effects of 8‐iso PGE2 and 8‐iso PGF2α did not involve elevation of [Ca2+]i. 8‐iso PGE2‐evoked contractions were blocked by inhibitors of tyrosine kinase (genistein) and Rho kinase (Y 27632 and HA 1077), but not by inhibitors of protein kinase C (calphostin C or chelerythrine), mitogen‐activated protein kinase kinase (PD 98059) or p38‐kinase (SB 203580). The actions of 8‐isoprostanes in the lungs are compound‐, species‐ and tissue‐dependent. Several isoprostanes evoke vasoconstriction: in the case of 8‐iso PGE2, this involves activation of TP‐receptors, tyrosine kinases and Rho kinases. 8‐iso PGE1 is also able to cause vasodilation. British Journal of Pharmacology (2001) 132, 127–134; doi:10.1038/sj.bjp.0703784